Salt: Ondansetron
Therapeutic Description: Antiemetics & Gastroprokinetics
Category: 5HT3-antagonist.
Pregnancy: No evidence of risk in humans.
Lactation: Caution advised or effect undetermined.
Precautions: Hepatic impairment, intestinal obstruction.
Nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Prophylaxis and treatment of postoperative nausea, vomiting.
Chemotherapy and radiotherapy: Highly emetogenic regimens: Adults: Single dose of 8 mg by slow IV inj immediately prior to chemotherapy; or 8 mg by slow IV inj prior to chemotherapy followed by either two doses of 8 mg by IV inj repeated 2-4 hours apart or by 1 mg per hour by IV infusion for up to 24 hours; or single dose of 32 mg in 50-100 mL saline infused over 15 min prior to chemotherapy. After first 24 hrs, follow by 8 mg orally twice daily for up to 5 days. Efficacy may be enhanced by addition of dexamethasone 20 mg IV prior to chemotherapy.
Less emetogenic regimens o
IM: Should be given undiluted. IV: Give first dose 30 min prior to beginning chemotherapy; the IV preparation has been successful when administered orally. IVPB: Infuse over 15-30 min; 24-hour continuous infusions have been reported, but are rarely used.
Phenytoin, rifampicin, carbamazepine, tramadol.
Constipation, headache, flushing. Transient rise in liver enzymes. Rarely hypersensitivity reactions, anaphylaxis, chest pain, ST segment depression, cardiac arrhythmia, hypotension, bradycardia, extrapyramidal reactions, seizures, visual disturbance.
Strength Pack Size PKR
4 mg5 Amp2700.00
8 mg5 Amp4525.66
4 mg30's6864.00
8 mg10's3795.79

Your medicine formula resulted in the following types of medicine type. Please select to proceed.